## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.8% in mid entry zone (3.0-6.0%), top quartile (82nd pct) cross-sectional ranking. Short-term MRS_5 (5.9%) confirms momentum alignment. Strong momentum (+9.4% 5-day acceleration). Outperforming sector by 3.2%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($52.63)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: GlobeNewswire | 20260105T083000 | Bullish | Relevance: 100%
- CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 8:15 a.m. PT in San Francisco. A live webcast and subsequent replay will be available on the company's investor relations website. CRISPR Therapeutics is a gene editing company developing transformative medicines, known for CASGEVYÂ®, the world's first CRISPR-based therapy.

**2. Assessing CRISPR Therapeutics (CRSP) Valuation As Investor Interest Returns**
- Source: Simply Wall Street | 20260105T080935 | Somewhat-Bullish | Relevance: 100%
- CRISPR Therapeutics (CRSP) has re-entered investor focus with a current share price of US$53.77 and mixed recent returns, suggesting renewed interest. The company's valuation is explored through its price-to-book ratio and a discounted cash flow model, indicating it might be undervalued compared to peers and its intrinsic worth despite ongoing losses. Investors are encouraged to consider the potential upsides alongside the risks associated with its pipeline programs.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | Needham | $80 | $80 | 0% |
| 2025-12-23 | Citizens | $86 | $86 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | Needham | reit | Buy |
| 2025-12-23 | Citizens | reit | Market Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 7 ($4.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $4.0M in recent transactions.
2. High short interest (25.8%, 10.4 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +9.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1964% YoY. Insider selling cluster ($4.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.5B |
| Beta | 1.70 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 25.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -4.5% to 4.8% (+9.4% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 82nd percentile. MRS_5 at 5.9% confirms short-term momentum alignment. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +MUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.83% (CS: 83) | Strong |
| RSI_14 | 57.5 | Neutral |
| MACD Histogram | 0.14 | Bullish |
| vs SMA20 | 1.042x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.125x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $58.19
- **Stop Loss:** $52.63 (9.6% risk)
- **Target:** $66.53 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 237
- **Position Value:** $13,791.03
- **Portfolio %:** 13.79%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*